Showing results (131-140 of 139) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 139 results.
Clinical Breast Cancer|March 9, 2021
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA StudyTsutomu Takashima, Fumikata Hara, Takayuki Iwamoto, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 5, 2005
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]Takahito Nakagawa, Hiromasa Takahashi, Toshiya Kamiyama, et al.
BMC Cancer|January 8, 2021
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BCKatsuhiko Nakatsukasa, Naoki Niikura, Kosuke Kashiwabara, et al.
Nature Cell Biology|December 19, 2006
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1Miki Nishio, Ken-ichi Watanabe, Junko Sasaki, et al.
Breast Cancer Research and Treatment|December 22, 2014
Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysisNaoki Hayashi, Naoki Niikura, Norikazu Masuda, et al.
Breast Cancer Research and Treatment|August 10, 2014
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysisNaoki Niikura, Naoki Hayashi, Norikazu Masuda, et al.
Annals of Translational Medicine|May 14, 2021
Oral care and oral assessment guide in breast cancer patients receiving everolimus and exemestane: subanalysis of a randomized controlled trial (Oral Care-BC)Masahiro Umeda, Yoshihide Ota, Kosuke Kashiwabara, et al.
The Oncologist|February 12, 2020
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III TrialNaoki Niikura, Katsuhiko Nakatukasa, Takeshi Amemiya, et al.
Breast Cancer (Tokyo, Japan)|May 20, 2025
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancerTetsuhiro Yoshinami, Yuko Takano, Yukinori Ozaki, et al.
Pageof 14